AngioScore, Inc. Announces Completion of Enrollment in Drug-Coated AngioSculpt® Scoring Balloon Catheter First-in-Human Study
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
FREMONT, Calif.--(BUSINESS WIRE)--AngioScore, Inc., a developer of novel angioplasty catheters for use in the treatment of cardiovascular disease, today announced the completion of enrollment in the Drug-Coated AngioSculpt Scoring Balloon Catheter First-in-Human (FIH) Study (“PATENT-C”). AngioScore anticipates that preliminary data from this study will be available for presentation at the Transcatheter Cardiovascular Therapeutics (TCT) conference to be held this fall in San Francisco.
Help employers find you! Check out all the jobs and post your resume.
FREMONT, Calif.--(BUSINESS WIRE)--AngioScore, Inc., a developer of novel angioplasty catheters for use in the treatment of cardiovascular disease, today announced the completion of enrollment in the Drug-Coated AngioSculpt Scoring Balloon Catheter First-in-Human (FIH) Study (“PATENT-C”). AngioScore anticipates that preliminary data from this study will be available for presentation at the Transcatheter Cardiovascular Therapeutics (TCT) conference to be held this fall in San Francisco.
Help employers find you! Check out all the jobs and post your resume.